meclofenamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory, anthranilic acid derivatives | 1650 | 644-62-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 19.30 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 65.10 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 25, 1980 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Intestinal diaphragm disease | 35.64 | 23.23 | 3 | 3 | 107 | 63488909 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AG04 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Fenamates |
| ATC | M02AA18 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
| CHEBI has role | CHEBI:35493 | anti-pyretic |
| CHEBI has role | CHEBI:35544 | cyclooxygenase inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| CHEBI has role | CHEBI:35623 | anticonvulsants |
| CHEBI has role | CHEBI:35842 | anti-rheumatic drugs |
| CHEBI has role | CHEBI:64964 | 5delta-lipoxygenase inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pain | indication | 22253000 | |
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Dysmenorrhea | indication | 266599000 | |
| Menorrhagia | indication | 386692008 | |
| Osteoarthritis | indication | 396275006 | |
| Ankylosing spondylitis | off-label use | 9631008 | DOID:7147 |
| Vascular headache | off-label use | 128187005 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Coronary artery bypass graft | contraindication | 232717009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Peripheral edema | contraindication | 271809000 | |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Smokes tobacco daily | contraindication | 449868002 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Chronic inflammatory disease involving the musculoskeletal system | Indication |
| Horses | Inflammatory diseases involving the musculoskeletal system | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Arquel Granules | Zoetis Inc. | 1 |
| Arquel Tablets | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.2 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Arachidonate 5-lipoxygenase | Enzyme | INHIBITOR | IC50 | 4.33 | WOMBAT-PK | CHEMBL | |||
| Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 6.66 | WOMBAT-PK | CHEMBL | |||
| Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 6.70 | WOMBAT-PK | CHEMBL | |||
| Aldo-keto reductase family 1 member C1 | Enzyme | IC50 | 5.50 | CHEMBL | |||||
| Aldo-keto reductase family 1 member C2 | Enzyme | IC50 | 5.06 | CHEMBL | |||||
| Aldo-keto reductase family 1 member C3 | Enzyme | IC50 | 6.27 | CHEMBL | |||||
| Fatty acid-binding protein, intestinal | Cytosolic other | Ki | 5.05 | CHEMBL | |||||
| Transient receptor potential cation channel subfamily M member 4 | Ion channel | BLOCKER | IC50 | 5.47 | IUPHAR | ||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 5.50 | DRUG MATRIX | |||||
| Transthyretin | Secreted | IC50 | 4.30 | CHEMBL | |||||
| Androgen receptor | Nuclear hormone receptor | IC50 | 4.19 | WOMBAT-PK | |||||
| Fatty acid-binding protein, liver | Unclassified | Ki | 6.59 | CHEMBL | |||||
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 6.70 | CHEMBL | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 7.30 | CHEMBL | |||||
| Arachidonate 5-lipoxygenase | Enzyme | IC50 | 4.62 | CHEMBL | |||||
| Cyclooxygenase | Enzyme | IC50 | 7 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019080 | VUID |
| N0000147341 | NUI |
| D00169 | KEGG_DRUG |
| 67254-91-5 | SECONDARY_CAS_RN |
| 4019079 | VANDF |
| 4019080 | VANDF |
| 4022843 | VANDF |
| C0025042 | UMLSCUI |
| CHEBI:6710 | CHEBI |
| JMS | PDB_CHEM_ID |
| CHEMBL509 | ChEMBL_ID |
| CHEMBL876 | ChEMBL_ID |
| CHEMBL1562610 | ChEMBL_ID |
| DB00939 | DRUGBANK_ID |
| D008469 | MESH_DESCRIPTOR_UI |
| 4037 | PUBCHEM_CID |
| 7219 | IUPHAR_LIGAND_ID |
| 2165 | INN_ID |
| 48I5LU4ZWD | UNII |
| 588003 | RXNORM |
| 1713 | MMSL |
| 5031 | MMSL |
| d00283 | MMSL |
| 002387 | NDDF |
| 002388 | NDDF |
| 117178002 | SNOMEDCT_US |
| 58233009 | SNOMEDCT_US |
| 770315008 | SNOMEDCT_US |
| 96172003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Meclofenamate Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2150 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
| Meclofenamate Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3000 | CAPSULE | 100 mg | ORAL | ANDA | 27 sections |